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Summary: Conclusive evidence of a polyuric etiology from a failure of vasopressin
elevation led to a new pharmacologic approach to the treatment of childhood nocturnal
enuresis. Desmopressin acetate, a vasopressin analogue, has been used successfully since
1978 to treat this condition. Desmopressin’s efficacy at doses of 5 to 40 &mu;g has been
demonstrated in Europe and the United States. Similarly, its safety has been established,
and it is a first-line choice for physicians worldwide.
Introduction
edwetting is an integral,
normal part of develop-
ment in young children in
whom sleep duration may exceed
bladder capacity and arousal mech-
anisms may be immature. In fact,
deferred nocturnal vasopressin am-
plification is probably an important
physiologic device in young chil-
dren, and physicians should gen-
erally be reluctant to consider
nocturnal enuresis a condition
requiring medical attention in
children under 7 years of age.
Management choices presently
available for nocturnal enuresis
can be grouped into three catego-
ries. The first is actually no man-
agement, i.e., waiting for
spontaneous resolution, which is
likely in most children, particularly
in the first 7 years of life. Attempt-
ing to achieve control in very
young children is inadvisable: fluid
restriction usually offers no relief,
lifting at night is often unnecessar-
ily disruptive to parents as well as
children, and discipline is only to
be condemned.
In some children with nocturnal
enuresis, particularly those over 7
years of age, the potential for loss
of self-esteem and social stigmatiza-
tion may make intervention a logical
choice. In such cases, a bell and pad
moisture-sensing device, or alarm,
is a typical starting point. Prereq-
uisites for using alarms are a moti-
vated child and family. Even then,
this technique may be ineffective,
and when the bedwetter must share
a room, alarms are less practical.
The third option is medical in-
tervention, i.e., augmenting noc-
turnal water conservation with the
use of a vasopressin analogue such
as desmopressin acetate.
An overview of the American ex-




In 1897, in TheDiseases of Infancy
and Childhood, which is the classic
and perhaps best early American
pediatric textbook, L. Emmett
Holt, an eminent pediatrician in
New York City, discussed the mani-
fold aspects of nocturnal enuresis.
Holt recognized several causes for
nocturnal enuresis. He did not an-
ticipate the polyuric explanation
favored today but thought instead
that, when the urine itself was the
causative factor, it was because of
acidity. Other possible causes con-
sidered by Holt included constitu-
tional disease, neurosis, phimosis,
pinworms, and bladder calculus.
Among acceptable treatments
Holt listed meatotomy, circumci-
sion, urine alkalinization, and the
use of galvanism, belladonna,
and strychnine. After Holt, the
pharmacologic treatment of noc-
turnal enuresis remained largely
empirical until the demonstra-
tion of a polyuric etiology from a






a vasopressin analogue, was initially
used with great success in children
with diabetes insipidus.’ The first
clinical trials that used intranasal
desmopressin to treat bedwetting
in children were conducted in
Europe in 1978. In a Swedish study
of 18 children with primary noctur-
nal enuresis,4 Tuvemo reported ex-
cellent results in eight children,
relatively good results in eight, and
unsatisfactory results in two. Des-
mopressin was used in a 20 pg /day
dosage. Birkdsovd et al5 used des-
mopressin at dosages of 10 and 40
j-Lg to treat 22 Czechoslovakian chil-
dren (mean age, 6.6 ± 2.9 years)
with persistent nocturnal enuresis.
Eighteen children responded fa-
vorably to the drug. Five of these
who received the 40-gg dose had a
&dquo;dramatic&dquo; response.
At the time of these studies, the
primary nonpharmacologic tool
for nocturnal enuresis was the
moisture-sensing alarm and the
main therapeutic agent was imip-
ramine.6 Imipramine, which has
both central nervous and bladder
actions, continues to be widely
used for this purpose today. Oxy-
butynin chloride, an anticholiner-
gic, is also effective but in a lesser
number of children; the most
likely to benefit from this agent are
patients with detrusor instability, a
relatively uncommon cause of iso-
lated nocturnal enuresis.
No evidence of any major differ-
ences in toilet training habits or
bedwetting patterns has been
noted between Western European
and North American children.
Consequently, the American expe-
rience with desmopressin for noc-
turnal enuresis has generally
followed the lead of European in-
vestigators. In 1983, Post et al re-
ported an American double-blind,
crossover study of desmopressin
for nocturnal enuresis in 52 pa-
tients at three medical centers
Results demonstrated a 75% re-
duction in the frequency of wet
nights; no patient had significant
side effects. The best response,
achieved in 12% of the children,
was defined as 13 to 14 dry nights
in the 2-week treatment period.
Dosages were 20 and 40 jig/day.
The drug appeared most effective
in children over 9 years of age,
among whom 71 % responded with
8 to 14 dry nights in the 2-week test.
The larger dose was more effective
in reducing the number of wet
nights than the lower dose.
In 1989, Klauber reviewed 12
placebo-controlled trials con-
ducted at 15 sites worldwide and
consisting of 495 children and 21
adults.’ The three American trials
in that review included 276 pa-
tients at multiple study sites. Al-
most all patients had been resistant
to prior therapy. Desmopressin
doses were 20 to 40 jig adminis-
tered intranasally. Results, re-
ported as the percent fewer wet
nights while taking desmopressin,
varied from 24% to 65% with an
average of 28.6%. For example, in
one of the trials using 40 pg of
desmopressin, there was a reduc-
tion of 3.7 wet nights compared
with baseline in the initial 2 weeks
of treatment, and a further reduc-
tion of 0.5 wet nights in the second
2 weeks for a total mean reduction
of 4.2 (34%) wet nights for the
study period. This result was not
seen with either placebo or the 20-
gg dose. Klauber commented that
&dquo;there are many problems and
variables with drug trials in enure-
sis.&dquo; Patients most likely to be in-
cluded in such trials have had the
most intractable disease states and
generally have been unrespon-
sive to previous therapy. These
patients can be expected to have
less response to medication than
unselected or previously untreated
patients. Even so, after analysis of
the many different studies, Klauber
concluded that desmopressin un-
questionably increased the num-
ber of dry nights in bedwetters
compared with their own baselines
and placebo. The 40-¡..tg dose
seemed to be more effective than
20 pg and the drug appeared to be
safe: there were no serious adverse
reactions in the 516 patients. Im-
portantly, almost all were resistant to
previous treatment for nocturnal
enuresis.
Miller, Goldberg, and Atkin,
also in 1989, reported on the use of
40 pg of desmopressin in 55 chil-
dren (46 boys, 9 girls) with noctur-
nal enuresis.9 The patients were 6
to 17 years old and all were fre-
quent bedwetters (3 or more
nights/week) except for one girl
(2 nights/week) and all had been
refractory to other prior thera-
pies. A positive response was de-
fined as a reduction of wet nights
by at least 50% or a decrease in the
amount of wetness of the bed or
pad in terms of parental percep-
tion. After a positive response was
identified, the dose was systemati-
cally titrated down. In this 8-year
study, four patient groups were rec-
ognized : nonresponders (19), par-
tial responders (8), full responders
on desmopressin (13), and full re-
sponders who had discontinued
treatment and remained dry (15).
Among the responders who re-
mained dry off desmopressin, the
duration of therapy varied from 3
to 36 months (average, 13.5) and
the dry time off therapy was 6 to 84
months (average, 43). The respond-
ers still receiving desmopressin
had therapy durations of 3 to 42
months (average, 9.9 months).
Miller and Klauber’s 1990 up-
date of these American trials con-
firmed the safety and efficacy of
desmopressin.l° In two US mul-
ticenter studies, 176 children with
30
primary nocturnal enuresis re-
ceived 20 or 40 pg of desmopressin
or placebo for 4 weeks. This dou-
ble-blind treatment phase was fol-
lowed by a 4-week, open-label
period during which all patients
received either 20 or 40 jig of the
drug. Children on desmopressin
had significantly fewer wet nights
than those on placebo, and those
crossed over from placebo to des-
mopressin showed similar reduc-
tions in nocturnal enuresis.
Desmopressin was more effective
at the higher dose. In 1992, Miller,
Atkin, and Moody surveyed the
previous experience with desmo-
pressin and added their own find-
ings.ll They found desmopressin
most effective at the 40-Rg dose.
Once dryness was attained, the
dose was titrated downward.
Although not a clinical trial, a
single-center experience with des-
mopressin revealed a substantial
number of children dry at the low
desmopressin dose of 5 ~g.12 As in
the initial European experience,
desmopressin was used when other
therapeutic modalities failed on
the assumption that at least some
of the children with refractory
nocturnal enuresis had, in a
sense, nephrogenic diabetes in-
sipidus. In the absence of any
other delivery system, the rhinal
tube was utilized with initial dos-
ing at 5 jig and titrated upward as
needed. Approximately 25% of
the patients improved and were
maintained on the 5-Rg dose and
more than half were maintained
effectively on 10 pg. The criteria
for success in this group of chil-
dren was defined as a decrease in
the number of recorded wet nights
per week. During treatment, 54%
of the children reported complete
nighttime dryness and 38% had a
decrease in wet nights. These data
suggest a relatively low dose of des-
mopressin is effective in some chil-
dren. The advantage of low dosing
is primarily that of cost. The 5-)lg
rhinal tube is difficult to use, how-
ever, and when the spray applicator
became commercially available in
1989, convenience overcame cost,




The efficacy of desmopressin
has been substantiated by 14 years
of Western European and North
American clinical experience with
the drug. In many centers, it has
become the pharmacologic agent
of first choice and its safety with
careful use was established during
those years. Rare reports of serious
side effects indicate that cystic fi-
brosis, nasal polyps, and unmoni-
tored, unsupervised usage are
contraindications to desmopressin
therapy.13-15 Patients and families
should be given a handout explain-
ing the rules of treatment and signs
of complications. Soon after ther-
apy has begun, we check a morning
set of electrolytes and monitor pa-
tients for dosing adjustments.
Expectations
Disparate definitions of satisfac-
tory effect and flexible interpreta-
tions of data complicate most
pharmacologic studies of noctur-
nal enuresis. The hope for a bed-
wetter who is brought to treatment
is that the problem will be solved.
It is clear from the literature, how-
ever, that this expectation is not
always realized, although the prob-
lem is likely to be improved. For
this reason, it is mandatory to have
some objective sense of the magni-
tude of the bedwetting, i.e., how
many wet nights a week a given
child typically experiences. This in-
formation may be difficult to elicit
given the variability of symptoms in
some children, the denial of enu-
resis in others, and the unwilling-
ness of child or family to keep an
elimination diary. Nevertheless,
therapy should be unthinkable
without a careful elimination his-
tory that includes documentation
of the degree of incontinence. 16
Conclusion
Staying dry through the night is
a function of maturation, which
varies from child to child; not all
bedwetters require therapy. The
majority of bedwetters seem to
have a nocturnal polyuric factor
that is amenable to replacement
therapy with a vasopressin ana-
logue such as desmopressin ace-
tate. The American experience
with desmopressin substantiates
the European experience: desmo-
pressin is an effective agent for the
treatment of nocturnal enuresis
and is a first-line choice for physi-
cians worldwide.
In a larger context, William
Carlos Williams, a poet and physi-
cian from NewJersey, described the
discovery of this continent in terms
of the ambiguity of wetness and
dryness: &dquo;The New World, existing
in those times beyond the sphere
of all things known to history, lay in
the fifteenth century as the middle
of the desert or the sea ... &dquo;17 In a
smaller sense we recapitulate a bit
of that dichotomy; over the long
run in life we prefer to stand on dry
land and to sleep in dry beds, but
sometimes along the way circum-
stances and homeostasis tolerate
and even demand the wet milieu.
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